Recently, PARPis, which target the key enzyme PARP in DNA damage response, have demonstrated potent antitumor effects due to synthetic lethality exerted on tumor cells deficient in DNA damage repair, most remarkably those with BRCA1/2 mutations (1, 2). This evidence concerns the gene BRCA1 and neoplasm.